Summary of Aipeng Medical Conference Call Company Overview - Aipeng Medical is focused on developing advanced medical devices in the field of brain-machine interfaces, particularly in anesthesia monitoring, sleep treatment, and ADHD management. The company has established partnerships with various hospitals and academic institutions to enhance its product offerings and research capabilities [2][4][7]. Key Products and Developments 1. **Anesthesia Depth Monitoring Device** - The device has been implemented in over 100 hospitals and is expected to generate revenue exceeding 10 million yuan by 2025. It collects prefrontal EEG signals to output anesthesia indices during surgery, preventing awareness or excessive anesthesia [2][6]. 2. **Sleep Treatment Solutions** - Aipeng Medical has developed a neural regulation and bionic sleep solution targeting approximately 10 million patients with chronic insomnia. This includes diagnostic tools (PSG and adhesive sleep monitoring) and treatment options (self-controlled sedation and auricular vagus nerve stimulation). The system is valued at hundreds of thousands to millions of yuan per unit and is already in use in several hospitals [2][4][7]. 3. **ADHD Management System** - The company has created a multimodal behavioral management system for over 20 million children with ADHD, incorporating EEG headsets, drones, and robots. This system is currently being utilized in a few hospitals and is supported by a joint laboratory established with Fudan University Children's Hospital [2][4][7]. 4. **Epilepsy Monitoring and Warning System** - Aipeng Medical is researching a semi-implantable real-time monitoring and warning system for epilepsy, with plans to launch a prototype in the second half of 2026 and obtain certification by 2029 [2][10][12]. 5. **Non-Invasive Brain Stimulation Technology** - The company is collaborating with Ruishen An to develop non-invasive deep electrode stimulation technology, with projected revenue exceeding 100 million yuan by 2025 [3][10]. Financial Projections - For 2026, Aipeng Medical anticipates revenue from heart and brain state monitoring to be less than 20 million yuan, while combined revenue from ADHD and sleep systems is expected to reach several tens of millions. The company aims to scale these operations to over 100 million yuan as quickly as possible, with marketing strategies to be adjusted based on clinical discussions and pricing [5][11]. Research and Development Strategy - Aipeng Medical has established an Artificial Intelligence and Brain-Machine Engineering Research Institute, leveraging internal and external expert resources to accelerate product innovation. The internal team includes researchers from prestigious universities and experienced professionals from leading tech companies [4][7][15]. Market Strategy and Commercialization - The company emphasizes the importance of clear application scenarios for the commercialization of brain-machine interface technology. Aipeng Medical aims to build credibility through hospital endorsements and expand into consumer markets, particularly in sleep treatment, by integrating hospital and home care solutions [17][18]. Future Plans - Aipeng Medical plans to continue advancing its non-invasive product lines, including the ADHD training system and sleep treatment solutions. The company is also focused on developing the appetite interference stimulation system and progressing the semi-invasive epilepsy warning device. Additionally, it is exploring embedded neural regulation devices in collaboration with leading domestic companies [18].

Group 1: Stock Market Activity - On the day, 41 stocks were listed on the institutional trading leaderboard, with 20 stocks seeing net purchases and 21 stocks experiencing net sales [1] - The top three stocks with the highest net purchases by institutions were Aerospace Electric (276 million), Zhenlei Technology (259 million), and Luyan Pharmaceutical (187 million) [1] Group 2: Aerospace Industry Insights - Aerospace Electric, a leading manufacturer of aerospace connectors, has a market share exceeding 70% and received a net purchase of 276 million from two institutions [3] - The company has successfully applied gallium arsenide solar cell epitaxial wafers and chips in the commercial aerospace sector, maintaining the highest domestic market shipment volume [3] - The construction of China's first rocket recovery and reuse base, Arrow Yuan Technology, has commenced, indicating a significant development in the aerospace industry [3] Group 3: SpaceX and Market Valuation - SpaceX's IPO is expected to set a new valuation ceiling for commercial aerospace, with a current market valuation of 800 billion USD and a planned IPO valuation of 1.5 trillion USD by 2026 [4] - The anticipated revenue target of 23 billion USD for 2026 could result in a dynamic price-to-sales ratio of 65, reflecting strong market confidence in the commercial aerospace sector [4] Group 4: Solar Technology in Aerospace - The solar wing is identified as a core energy device for spacecraft, with flexible solar wings expected to be the future choice due to their advantages [5] - Gallium arsenide remains the mainstream technology for solar cells, while silicon-based materials are being utilized in Starlink satellites, and perovskite technology shows significant future potential due to its cost-effectiveness [5] Group 5: Brain-Computer Interface Market - Cere Medical has signed a strategic cooperation agreement with Huawei and a national key laboratory to focus on precision diagnosis and treatment of mental disorders using AI [6] - The brain-computer interface market is projected to reach approximately 3.19 billion USD by 2025, with significant growth expected in medical applications by 2030 and 2040 [6][7] - The domestic brain-computer interface market in China is expected to exceed 3.8 billion CNY by 2025, with a sustained annual growth rate of about 20% [7]

Summary of Aipeng Medical Conference Call Company Overview - **Company**: Aipeng Medical - **Industry**: Non-invasive brain-computer interface (BCI) technology Key Points Business Applications and Revenue - Aipeng Medical has multiple applications in the non-invasive BCI field, including: - Anesthesia depth monitoring device with approximately 10 million yuan in revenue [2][4] - Treatment system for refractory insomnia, already implemented in Shenzhen [2][8] - ADHD behavior management system, combining EEG technology and data platforms [2][5] - The anesthesia depth monitoring device market potential is significant, with a device market size nearing 1 billion yuan and consumables market exceeding 4 billion yuan [2][7] - The company aims to achieve revenue growth through partnerships with hospitals, targeting around 100 patients per hospital for the insomnia treatment system, potentially generating millions in revenue [2][12] Market Potential and Growth - The refractory insomnia treatment system targets approximately 6 million patients in China, with a market strategy involving collaboration with multiple hospitals [2][8] - The ADHD behavior management system addresses over 20 million affected children, with a commercial revenue forecast of up to 100 million yuan annually, contingent on treatment rates [2][9] Product Development and Innovations - Aipeng Medical is developing a semi-invasive epilepsy warning system that provides alerts 3-5 minutes in advance using flexible electrodes [2][6] - The company has a stake in Changzhou Ruishen'an, focusing on implanted neuro-regulation products, with plans to launch an upgraded DBS product by 2025 [2][11] - Future product development includes a semi-invasive epilepsy monitoring prototype and ongoing research projects in the BCI field [2][15][16] Competitive Landscape and Market Strategy - The pain management business has maintained a 23% market share despite competitive pressures, covering 2,800 hospitals [2][17] - The nasal care segment faces intense competition, prompting a shift to an OTO model and the development of new drug-device combination products [2][17] - The company is focusing on enhancing its competitive edge through strategic adjustments and product innovation [2][17] Financial Projections - For 2026, Aipeng Medical anticipates modest growth in pain management revenue and stable performance in nasal care, while BCI revenue is projected between 30-50 million yuan [2][18] - The company expects overall revenue growth, although BCI business profits may be lower due to high R&D investments [2][18] Team and Expertise - The BCI team comprises experts from various prestigious institutions, enhancing the company's research and development capabilities in sensor technology, neural algorithms, and embedded systems [2][19] Future Directions - Aipeng Medical plans to expand its BCI business, focusing on both non-invasive and invasive technologies, while accumulating core technical expertise [2][20]

Core Viewpoint - The company has developed a multimodal ADHD behavior training system that connects data between in-hospital behavior training centers and at-home training scenarios, utilizing scientific EEG monitoring and multimodal intervention training to help children improve hyperactivity and attention deficit behaviors, enhancing focus [2] Group 1 - The company possesses a deep technical reserve in anesthesia depth monitoring, being one of the few in China to master anesthesia depth index monitoring, which is crucial for perioperative monitoring, diagnosis, and early warning applications [2] - The company has launched a stubborn insomnia anesthesia treatment system designed to meet clinical needs for stubborn insomnia, integrating both hardware and software to support clinical treatment through intelligent interaction between doctors and patients [2] - The company plans to advance clinical innovative applications in perioperative brain state monitoring, ADHD, sleep disorders, and epilepsy among other mental health conditions [2]

Core Viewpoint - The company Aipeng Medical (300753) is focusing on the development of a multimodal ADHD behavior training system that connects data between in-hospital behavior training centers and at-home training scenarios, utilizing scientific EEG monitoring and multimodal intervention training to help children improve hyperactivity and attention deficit behaviors, thereby enhancing concentration [1] Group 1 - The company has developed a multimodal ADHD behavior training system that integrates data from both hospital and home environments [1] - The system employs scientific EEG monitoring and multimodal intervention training methods to assist children in improving hyperactivity and attention deficit behaviors [1] - The company possesses advanced technology in anesthesia depth monitoring, being one of the few in China to master anesthesia depth index monitoring [1] Group 2 - Aipeng Medical has launched a stubborn insomnia anesthesia treatment system designed to meet clinical needs for treating persistent insomnia, combining hardware and software solutions [1] - The system addresses the digital interaction needs between doctors and patients both in and out of the hospital, providing strong support for clinical treatment [1] - The company plans to advance clinical innovative applications in perioperative brain state monitoring, ADHD, sleep disorders, and epilepsy treatment [1]

Group 1 - The Jiangxi Provincial Government is accelerating the clinical research of brain-computer interface technology in the treatment of neurological and psychiatric diseases, as well as in elderly rehabilitation [1] - The government supports medical institutions in establishing clinical research wards and cohorts for brain-computer interface technology [1] - The establishment of the Jiangxi Brain-Computer Interface Rehabilitation Center and high-quality data sets for the EEG industry in the Ganjiang New Area is also being promoted [1] Group 2 - Aipeng Medical (300753.SZ) confirmed that its perioperative brain state monitoring product, the anesthesia depth monitor, has generated sales revenue in Jiangxi Province, although the revenue impact is relatively small [1]

Core Viewpoint - Aipeng Medical (300753) is responding to investor inquiries regarding the advancement of brain-computer interface technology in clinical research for neurological and psychiatric diseases, as well as rehabilitation for the elderly in Jiangxi Province [1] Group 1: Company Response - Aipeng Medical has reported that its perioperative brain state monitoring product, the anesthesia depth monitor, has generated sales revenue in Jiangxi Province, although the revenue contribution is relatively small [1] Group 2: Industry Context - The Jiangxi Provincial Government has issued measures to accelerate the development of brain-computer interface technology and industry, emphasizing the need for clinical trials and the establishment of clinical research wards and cohorts in medical institutions [1] - The government supports the construction of a rehabilitation center for brain-computer interfaces and a high-quality data set for the EEG industry in the Ganjiang New Area [1]

Core Viewpoint - Aipeng Medical (300753) is focusing on the medical device sector, particularly in pain management and upper airway management, while also expanding into brain-computer interface innovations [1] Group 1: Business Focus - The company is engaged in two main segments: acute and chronic pain management, and nasal and upper airway management [1] - Aipeng Medical is actively developing brain-computer interface applications, including perioperative brain state monitoring and treatment systems for insomnia and ADHD [1] Group 2: Product Development - The company has developed a multimodal ADHD behavior management system that connects data from in-hospital training centers to home training environments, utilizing scientific EEG monitoring and multimodal intervention training [1] - Aipeng Medical possesses advanced technology in anesthesia depth monitoring, which is crucial for perioperative monitoring, diagnosis, and early warning applications [1] Group 3: Future Innovations - The company is researching a seizure warning platform and aims to advance clinical applications for perioperative brain state monitoring, ADHD, sleep disorders, and epilepsy [1] - Aipeng Medical has invested in Ruishen'an Medical, which specializes in the development, production, and sales of brain nerve regulation and intracranial electrode medical devices [1]

Company Overview - Aipeng Medical focuses on medical devices, particularly in pain management and nasal airway management, while also exploring brain-computer interface (BCI) innovations [4] - The BCI applications include perioperative brain state monitoring, treatment systems for chronic insomnia, and ADHD behavior management systems [4] Product Development - The company has developed a non-invasive ADHD behavior management system that connects data between clinical and home settings, utilizing EEG monitoring and multimodal interventions [5] - Aipeng Medical possesses a depth of technology in anesthesia depth monitoring, being one of the few companies in China to master this technology [6] - The chronic insomnia treatment system is designed to meet clinical needs and supports both in-hospital and remote patient interactions [6] Market Expansion - Several provinces in China, including Hubei, Zhejiang, and Guangdong, have begun to reimburse BCI medical services, facilitating the clinical application of BCI technologies [7] - The new generation ADM series anesthesia depth monitors have received three registration certificates and have been launched in over 20 provinces [7] - The company has established a joint laboratory with Fudan University to integrate research and clinical applications for ADHD treatment [7] Consumer Products - The chronic insomnia treatment system and ADHD behavior management system are designed for both clinical and consumer markets, with specific products for hospital and home use [8] - The ADHD training products include both hospital and home versions, with a focus on serious medical applications before expanding to consumer markets [8] Data Construction and R&D Investment - The chronic insomnia treatment system includes comprehensive data tracking for patient interactions, treatment monitoring, and ongoing data collection [9] - Aipeng Medical is committed to enhancing its R&D capabilities and fostering collaborations with academic institutions to drive innovation in BCI applications [10]

Investment Rating - The investment rating for the pharmaceutical and biotechnology industry is "Positive" (maintained) [1] Core Insights - The brain-computer interface (BCI) technology is experiencing rapid development and has promising commercial prospects, with a focus on diverse technical paths and applications in the medical field [5][6][32] - The BCI technology is categorized into invasive, semi-invasive, and non-invasive types, each with its own advantages in signal quality, safety, and operational difficulty [18][20] - The core technological barriers of BCI are concentrated in the upstream of the industry chain, including hardware (electrodes, chips), surgical procedures, and signal processing [25][28] Summary by Sections 1. BCI Development and Applications - BCI is a multidisciplinary technology that integrates neuroscience, computer science, and engineering to facilitate communication between the brain and external devices [15] - The medical application of BCI is predominant, accounting for 56% of the market in 2023, with potential in diagnosing and treating cognitive disorders, mental illnesses, and motor disabilities [33][36] 2. BCI Policy and Pricing - The National Healthcare Security Administration has established a pricing standard for BCI services, addressing the slow commercialization of BCI technology and creating a pricing framework that covers the entire service chain [40][42] 3. BCI Companies and Market Trends - Non-invasive BCI products are leading in commercialization, while invasive and semi-invasive products are still in clinical research stages [43] - Key companies in the BCI space include NeuroPace, BrainGate, Neuralink, and Paradromics, each focusing on various applications such as epilepsy treatment and motor function recovery [43]